Evidence map›Paper›PMID 36644825›Full record

ArticleProtein science : a publication of the Protein Society2023

ScrepYard: An online resource for disulfide-stabilized tandem repeat peptides.

Junyu Liu, Michael Maxwell, Thom Cuddihy, Theo Crawford, Madeline Bassetti, Cameron Hyde, Steve Peigneur, Jan Tytgat, Eivind A B Undheim, Mehdi Mobli

Open access · hybridAbstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Structural Basis of the Bivalency of the TRPV1 Agonist DkTx.Angewandte Chemie (International ed. in English) · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. ScrepYard: An online resource for disulfide-stabilized tandem repeat peptides.Protein science : a publication of the Protein Society · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Junyu LiuCentre for Advanced Imaging, The University of Queensland, St. Lucia, Queensland, Australia.ORCID 0000-0002-8926-0161
Michael MaxwellCentre for Advanced Imaging, The University of Queensland, St. Lucia, Queensland, Australia.
Thom CuddihyQueensland Cyber Infrastructure Foundation Ltd., The University of Queensland, St. Lucia, Queensland, Australia.
Theo CrawfordCentre for Advanced Imaging, The University of Queensland, St. Lucia, Queensland, Australia.
Madeline BassettiQueensland Cyber Infrastructure Foundation Ltd., The University of Queensland, St. Lucia, Queensland, Australia.
Cameron HydeQueensland Cyber Infrastructure Foundation Ltd., The University of Queensland, St. Lucia, Queensland, Australia.ORCID 0000-0002-5913-9766
Steve PeigneurToxicology and Pharmacology, University of Leuven (KU Leuven), Leuven, Belgium.ORCID 0000-0003-0504-5702
Jan TytgatToxicology and Pharmacology, University of Leuven (KU Leuven), Leuven, Belgium.ORCID 0000-0003-1778-6022
Eivind A B UndheimCentre for Advanced Imaging, The University of Queensland, St. Lucia, Queensland, Australia.ORCID 0000-0002-8667-3999
Mehdi MobliCentre for Advanced Imaging, The University of Queensland, St. Lucia, Queensland, Australia.
The University of Queensland · AUKU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Receptor avidity through multivalency is a highly sought-after property of ligands. While readily available in nature in the form of bivalent antibodies, this property remains challenging to engineer in synthetic molecules. The discovery of several bivalent venom peptides containing two homologous and independently folded domains (in a tandem repeat arrangement) has provided a unique opportunity to better understand the underpinning design of multivalency in multimeric biomolecules, as well as how naturally occurring multivalent ligands can be identified. In previous work, we classified these molecules as a larger class termed secreted cysteine-rich repeat-proteins (SCREPs). Here, we present an online resource; ScrepYard, designed to assist researchers in identification of SCREP sequences of interest and to aid in characterizing this emerging class of biomolecules. Analysis of sequences within the ScrepYard reveals that two-domain tandem repeats constitute the most abundant SCREP domain architecture, while the interdomain "linker" regions connecting the functional domains are found to be abundant in amino acids with short or polar sidechains and contain an unusually high abundance of proline residues. Finally, we demonstrate the utility of ScrepYard as a virtual screening tool for discovery of putatively multivalent peptides, by using it as a resource to identify a previously uncharacterized serine protease inhibitor and confirm its predicted activity using an enzyme assay.

Indexed as

DisulfidesPeptidesAmino AcidsAmino Acid SequenceTandem Repeat SequencesAmino AcidsDisulfidesPeptidesbioactivebivalentdisulfide-richmultivalentpeptideSCREPssecreted proteinstandem-repeat

Identifiers

PMID36644825
PMCPMC9885460
OpenAlexW4316464267

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.